Is Spruce Biosciences Stock a Good Investment?
Spruce Biosciences Investment Advice | SPRB |
- Examine Spruce Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Spruce Biosciences' leadership team and their track record. Good management can help Spruce Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Spruce Biosciences' business and its evolving consumer preferences.
- Compare Spruce Biosciences' performance and market position to its competitors. Analyze how Spruce Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Spruce Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Spruce Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Spruce Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Spruce Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Spruce Biosciences Stock
Researching Spruce Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 47.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.34. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Spruce Biosciences recorded a loss per share of 0.95. The entity had not issued any dividends in recent years.
To determine if Spruce Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spruce Biosciences' research are outlined below:
| Spruce Biosciences generated a negative expected return over the last 90 days | |
| Spruce Biosciences has some characteristics of a very speculative penny stock | |
| Spruce Biosciences has high historical volatility and very poor performance | |
| Spruce Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (47.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Spruce Biosciences currently holds about 93.3 M in cash with (33.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Spruce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Spruce Biosciences, Inc. Receives 3.90 Consensus Target Price from Brokerages |
Spruce Biosciences Quarterly Cash And Short Term Investments |
|
Spruce Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spruce Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spruce Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Spruce Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Spruce Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.24 | -0.21 | 0.03 | 12 | ||
2023-05-15 | 2023-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2023-11-13 | 2023-09-30 | -0.35 | -0.3 | 0.05 | 14 | ||
2021-08-10 | 2021-06-30 | -0.45 | -0.5 | -0.05 | 11 | ||
2023-03-16 | 2022-12-31 | -0.53 | -0.47 | 0.06 | 11 | ||
2023-08-14 | 2023-06-30 | -0.39 | -0.32 | 0.07 | 17 | ||
2021-11-15 | 2021-09-30 | -0.57 | -0.49 | 0.08 | 14 | ||
2024-08-12 | 2024-06-30 | -0.32 | -0.22 | 0.1 | 31 |
Know Spruce Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Spruce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Spruce Biosciences backward and forwards among themselves. Spruce Biosciences' institutional investor refers to the entity that pools money to purchase Spruce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lion Point Capital, Lp | 2024-09-30 | 75 K | Northern Trust Corp | 2024-09-30 | 74.9 K | State Street Corp | 2024-09-30 | 64.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 40 K | Shay Capital Llc | 2024-09-30 | 38.1 K | Two Sigma Advisers, Llc | 2024-09-30 | 27.1 K | Two Sigma Investments Llc | 2024-09-30 | 23.4 K | Xtx Topco Ltd | 2024-09-30 | 19.1 K | Jane Street Group Llc | 2024-09-30 | 15.7 K | Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | The Carlyle Group Inc | 2024-09-30 | 2.9 M |
Spruce Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.74 M.Market Cap |
|
Spruce Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.44) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.41) | (0.44) | |
| Return On Equity | (0.72) | (0.68) |
Determining Spruce Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Spruce Biosciences is a good buy. For example, gross profit margin measures Spruce Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spruce Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Spruce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spruce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spruce Biosciences' management manipulating its earnings.
Evaluate Spruce Biosciences' management efficiency
Spruce Biosciences has return on total asset (ROA) of (0.3035) % which means that it has lost $0.3035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5755) %, meaning that it created substantial loss on money invested by shareholders. Spruce Biosciences' management efficiency ratios could be used to measure how well Spruce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 6, 2025, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.62. The current year's Other Current Assets is expected to grow to about 7.1 M, whereas Total Assets are forecasted to decline to about 89.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.79 | 1.48 | |
| Tangible Book Value Per Share | 1.79 | 1.48 | |
| Enterprise Value Over EBITDA | (0.40) | (0.42) | |
| Price Book Value Ratio | 1.33 | 1.39 | |
| Enterprise Value Multiple | (0.40) | (0.42) | |
| Price Fair Value | 1.33 | 1.39 | |
| Enterprise Value | 24.3 M | 23.1 M |
The strategic initiatives led by Spruce Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 2.369 |
Basic technical analysis of Spruce Stock
As of the 6th of January, Spruce Biosciences has the Coefficient Of Variation of 83542.75, semi deviation of 4.43, and Risk Adjusted Performance of 0.0092. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spruce Biosciences, as well as the relationship between them.Spruce Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spruce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spruce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spruce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spruce Biosciences' Outstanding Corporate Bonds
Spruce Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spruce Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spruce bonds can be classified according to their maturity, which is the date when Spruce Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
| SPR 9375 30 NOV 29 Corp BondUS85205TAN00 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SPRINT P 7625 Corp BondUS85207UAK16 | View |
Understand Spruce Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Spruce Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0092 | |||
| Market Risk Adjusted Performance | 0.0397 | |||
| Mean Deviation | 3.22 | |||
| Semi Deviation | 4.43 | |||
| Downside Deviation | 5.61 | |||
| Coefficient Of Variation | 83542.75 | |||
| Standard Deviation | 4.58 | |||
| Variance | 21.0 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0297 | |||
| Maximum Drawdown | 31.01 | |||
| Value At Risk | (5.36) | |||
| Potential Upside | 7.27 | |||
| Downside Variance | 31.44 | |||
| Semi Variance | 19.64 | |||
| Expected Short fall | (4.25) | |||
| Skewness | (1.10) | |||
| Kurtosis | 5.07 |
| Risk Adjusted Performance | 0.0092 | |||
| Market Risk Adjusted Performance | 0.0397 | |||
| Mean Deviation | 3.22 | |||
| Semi Deviation | 4.43 | |||
| Downside Deviation | 5.61 | |||
| Coefficient Of Variation | 83542.75 | |||
| Standard Deviation | 4.58 | |||
| Variance | 21.0 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0297 | |||
| Maximum Drawdown | 31.01 | |||
| Value At Risk | (5.36) | |||
| Potential Upside | 7.27 | |||
| Downside Variance | 31.44 | |||
| Semi Variance | 19.64 | |||
| Expected Short fall | (4.25) | |||
| Skewness | (1.10) | |||
| Kurtosis | 5.07 |
Consider Spruce Biosciences' intraday indicators
Spruce Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Spruce Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 114765.0 | |||
| Daily Balance Of Power | (0.60) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 0.42 | |||
| Day Typical Price | 0.41 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.03) | |||
| Relative Strength Index | 29.87 |
Spruce Stock media impact
Far too much social signal, news, headlines, and media speculation about Spruce Biosciences that are available to investors today. That information is available publicly through Spruce media outlets and privately through word of mouth or via Spruce internal channels. However, regardless of the origin, that massive amount of Spruce data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spruce Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spruce Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spruce Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spruce Biosciences alpha.
Spruce Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Spruce Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Spruce Biosciences Corporate Management
| CPA CPA | Pres CFO | Profile | |
| MD III | Chief Officer | Profile | |
| Libbie MBA | Chief Officer | Profile | |
| P Ramtin | Senior Operations | Profile | |
| Heidi MPH | Senior Quality | Profile | |
| Kirk MD | Interim Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share | Quarterly Revenue Growth (0.80) | Return On Assets | Return On Equity |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Spruce Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.